ES2618352T3 - Antagonistas del receptor de prostaglandina D2 para el tratamiento de la alopecia androgenética - Google Patents

Antagonistas del receptor de prostaglandina D2 para el tratamiento de la alopecia androgenética Download PDF

Info

Publication number
ES2618352T3
ES2618352T3 ES07809581.7T ES07809581T ES2618352T3 ES 2618352 T3 ES2618352 T3 ES 2618352T3 ES 07809581 T ES07809581 T ES 07809581T ES 2618352 T3 ES2618352 T3 ES 2618352T3
Authority
ES
Spain
Prior art keywords
methyl
benzoyl
ylmethoxy
indole
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07809581.7T
Other languages
English (en)
Inventor
Luis Garza
George Cotsarelis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Application granted granted Critical
Publication of ES2618352T3 publication Critical patent/ES2618352T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0627—Hair cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0368—Animal model for inflammation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Environmental Sciences (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un antagonista del receptor de prostaglandina D2 (receptor DP) para su uso en el tratamiento de la alopecia androgenética (AAG) en el cuero cabelludo de un sujeto.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
En otra realización, el antagonista del receptor DP es una variante de la estructura anterior, en la que el grupo ciclopentilo de la derecha arriba está sustituido por un grupo ciclohexilo. Cada uno de los sustituyentes enumerados 5 para la estructura anterior puede usarse para esta estructura que contiene ciclohexilo.
En otra realización, el antagonista del receptor DP tiene una de las siguientes estructuras:
imagen7
7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
En otras realizaciones, el antagonista del receptor DP es una sal no tóxica de uno de los compuestos anteriores.
En otras realizaciones, el antagonista del receptor DP se selecciona entre los siguientes compuestos: (1) éster bencílico del ácido 1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético,
(2)
ácido 1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (3) ácido 1-(4-((2R)-1,4-benzodioxan-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (4) ácido 1-(4-((2S)-1,4-benzodioxan-2ilmetoxi)benzoil)-2-metil-1H-indolo-4-il-acético, (5) ácido 1-(4-((2S)-1-metilindolin-2-ilmetoxi)benzoil)-2-metil-1H-indol4-il-acético, (6) ácido 1-(4-((2R)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-ilacético, (7) ácido 1-(4-((2S)-4,6-dimetil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-ilacético, (8) ácido 1-(4-((2S)-6-fluoro-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-ilacético, (9) ácido 1-(4-((2S)-6-metoxi-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-ilacético, (10) ácido 1-(4-((2S)-7-metoxi-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-ilacético, (11) ácido 1-(4-((2S)-4,7-dimetil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4ilacético, (12) ácido 1-(4-((2 S)-7-fluoro-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4il-acético, (13) ácido 1-(4-((2S)-1-etilindolin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (14) ácido 1-(4-((2S)-4,8dimetil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (15) ácido 1-(4-((2S)-5-metoxi4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (16) ácido 1-(4-((2S)-5-fluoro4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (17) ácido 1-(4-((2S)-2,3dihidrobenzofuran-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (18) ácido 1-(4-((2R)-2,3-dihidrobenzofuran-2ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (19) ácido 1-(4-((2S)-8-fluoro-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2ilmetoxi)benzoil)-2-metil-1H-indol-4-ilacético, (20) ácido 1-(4-((2R)-1,4-benzoxatian-2-ilmetoxi)benzoil)-2-metil-1Hindol-4-il-acético, (21) ácido 1-(4-((3S)-2,3-dihidrobenzofuran-3-ilmetoxi)benzoil)-2-metil-1H-indol-4-ilacético, (22) ácido 1-(4-((3R)-2,3-dihidrobenzofuran-3-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (23) ácido 1-(4-((3R)-5-fluoro2,3-dihidrobenzofuran-3-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (24) ácido 1-(4-((3R)-5-metil-2,3dihidrobenzofuran-3-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (25) ácido 1-(4-((3R)-6-fluoro-2,3dihidrobenzofuran-3-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (26) ácido 1-(4-((3R)-7-metil-2,3dihidrobenzofuran-3-ilmetoxi)benzoil)-2-metil-1H-indol-4-ilacético, (27) ácido 1-(4-((2R)-5-fluoro-1,4-benzodioxan-2ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (28) ácido 1-(4-((2S)-8-fluoro-1,4-benzodioxan-2-ilmetoxi)benzoil)-2metil-1H-indol-4-il-acético, (29) ácido 1-(4-((3R)-7-fluoro-2,3-dihidrobenzofuran-3-ilmetoxi)benzoil)-2-metil-1H-indol-4il-acético, (30) éster alílico del ácido 3-(1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil1H-indol-4-il)acrílico, (31) ácido 3-(1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1Hindol-4-il)acrílico, (32) ácido 3-(1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol4-il)propanoico, (33) éster bencílico del ácido (1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2metil-1H-indol-4-il)oxiacético, (34) ácido (1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil1H-indol-4-il)oxiacético, (35) éster bencílico del ácido 1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2ilmetoxi)benzoil)-2-metil-1H-indol-4-carboxílico, (36) ácido 1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2ilmetoxi)benzoil)-2-metil-1H-indol-4-carboxílico, (37) éster bencílico del ácido 1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4benzoxazin-2-ilmetoxi)benzoil)-1H-indol-4-il-acético, (38) ácido 1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2ilmetoxi)benzoil)-1H-indol-4-il-acético, (39) ácido 1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)2,3-dihidro-1H-indol-4-il-acético, (40) ácido 1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2metil-2,3-dihidro-1H-indol-4-il-acético, (41) 2-(1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2metil-1H-indol-4-il)etanol, (42) 2-(1-(4-((2S)-4,6-dimetil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1Hindol-4-il)etanol, (43) 2-(1-(4-((2S)-6-fluoro-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1Hindol-4-il)etanol, (44) 2-(1-(4-((2S)-7-fluoro-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1Hindol-4-il)etanol, (45) 2-(1-(4-((2S)-2,3-dihidrobenzofuran-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il)etanol, (46) 2-(1-(4((3R)-2,3-dihidrobenzofuran-3-ilmetoxi)benzoil)-2-metil-1H-indol-4-il)etanol, (47) N-metilsulfonil-( 1-(4-((2S)-4-metil3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il)acetamida, (48) N-fenilsulfonil-(1-(4-((2S)-4metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il)acetamida, (49) acetato de 2-(1-(4-((2S)4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il)etilo, (50) éster bencílico del ácido 1(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)-2-metilbenzoil)-2-metil-1H-indol-4-il-acético, (51) éster bencílico del ácido 1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)-2-metilbenzoil)-1H-indol-4-il-acético,
(52)
ácido 1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)-2-metilbenzoil)-2-metil-1H-indol-4-il-acético, y
(53)
ácido 1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)-2-metilbenzoil)-1H-indol-4-il-acético o una sal no tóxica de los mismos.
En otras realizaciones, el antagonista del receptor DP tiene la estructura:
21
imagen21
en la que
R.sup.1 representa hidroxi, alcoxi C1-6, o NR.sup.8R.sup.9, en la que cada uno de R.sup.8 y R.sup.9 representa independientemente un átomo de hidrógeno, alquilo C1-6, o SO.sub.2R.sup.13, en la que R.sup.13 representa alquilo C1-6, un anillo carbocíclico saturado o insaturado C3-15 o un anillo heterocíclico de 4 a 15 miembros que contiene de 1 a 5 átomos de nitrógeno, átomos de azufre y/o átomos de oxígeno; R.sup.2 representa un átomo de hidrógeno, alquilo C1-6, alcoxi C1-6, alcoxialquilo C2-6, un átomo de halógeno, amino, trihalometilo, ciano, hidroxi, bencilo, o 4-metoxibencilo; R.sup.3 representa un átomo de hidrógeno, alquilo C1-6, alcoxi C1-6, un átomo de halógeno, trihalometilo, ciano, o hidroxi; cada uno de R.sup.4 y R.sup.5 representa independientemente un átomo de hidrógeno, alquilo C1-6, alcoxi C1-6, alcoxialquilo C2-6, un átomo de halógeno, nitro, amino, trihalometilo, ciano, o hidroxi; D representa un enlace sencillo, alquileno C1-6, alquenileno C2-6, u oxialquileno C1-6; en --G--R.sup.6,
1) G representa un enlace sencillo, alquileno C1-6 que puede estar sustituido con 1 a 2 átomos de oxígeno y/o átomos de azufre, alquenileno C2-6 que puede estar sustituido con 1 a 2 átomos de oxígeno y/o átomos de azufre, en la que el alquileno y el alquenileno pueden estar sustituidos con hidroxi o alcoxi C1-4, --C(O)NH--, --NHC(O)--, -SO.sub.2NH--,-NHSO.sub.2--, o diazo; R.sup.6 representa un anillo carbocíclico saturado o insaturado C3-15, o un anillo heterocíclico de 4 a 15 miembros que contiene de 1 a 5 átomos de nitrógeno, átomos de azufre y/o átomos de oxígeno, en la que el anillo puede estar sustituido con 1 a 5 sustituyentes seleccionados entre alquilo C1-6, alcoxi C1-10, alcoxialquilo C2-6, un átomo de halógeno, hidroxi, trihalometilo, nitro, amino, fenilo, fenoxi, oxo, acilo C2-6, alcanosulfonilo C1-6 y ciano,
2) G y R.sup.6 se toman juntos para representar
(i)
alquilo C1-15 que puede estar sustituido con 1 a 5 átomos de oxígeno y/o átomos de azufre;
(ii)
alquenilo C2-15 que puede estar sustituido con 1 a 5 átomos de oxígeno y/o átomos de azufre; o
(iii) alquinilo C2-15 que puede estar sustituido con 1 a 5 átomos de oxígeno y/o átomos de azufre, en la que el alquilo, el alquenilo y el alquinilo pueden estar sustituidos con 1 a 12 sustituyentes seleccionados entre alcoxi C1-6, un átomo de halógeno, hidroxi, ciano, oxo y NR.sup.11R.sup.12, en la que cada uno de R.sup.11 y R.sup.12 representa independientemente un átomo de hidrógeno, alquilo C1-6, alquenilo C2-6, fenilo, benzoílo, naftilo, fenilo sustituido con alquilo C1-6, o alquilo C1-6 sustituido con fenilo o ciano; n representa de 1 a 3; m representa de 1 a 3; i representa de 1 a 4; y
22
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40
imagen41
imagen42
imagen43
imagen44
imagen45
imagen46

Claims (1)

  1. imagen1
ES07809581.7T 2006-06-16 2007-06-15 Antagonistas del receptor de prostaglandina D2 para el tratamiento de la alopecia androgenética Active ES2618352T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US81404106P 2006-06-16 2006-06-16
US814041P 2006-06-16
US84516106P 2006-09-18 2006-09-18
US845161P 2006-09-18
PCT/US2007/014031 WO2007149312A2 (en) 2006-06-16 2007-06-15 Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and bph

Publications (1)

Publication Number Publication Date
ES2618352T3 true ES2618352T3 (es) 2017-06-21

Family

ID=38833999

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07809581.7T Active ES2618352T3 (es) 2006-06-16 2007-06-15 Antagonistas del receptor de prostaglandina D2 para el tratamiento de la alopecia androgenética

Country Status (10)

Country Link
US (3) US9254293B2 (es)
EP (2) EP3175856A1 (es)
CY (1) CY1118737T1 (es)
DK (1) DK2037967T3 (es)
ES (1) ES2618352T3 (es)
HU (1) HUE030850T2 (es)
PL (1) PL2037967T3 (es)
PT (1) PT2037967T (es)
SI (1) SI2037967T1 (es)
WO (1) WO2007149312A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060241696A1 (en) * 2005-04-26 2006-10-26 Stjepan Krco Method of limiting hair loss and promoting hair growth
US20150072963A1 (en) * 2006-06-16 2015-03-12 The Trustees Of The University Of Pennsylvania Compositions and methods for regulating hair growth
SI2037967T1 (sl) 2006-06-16 2017-04-26 The Trustees Of The University Of Pennsylvania Antagonisti receptorja za prostaglandin d2 za zdravljenje androgene alopecije
US8455547B2 (en) * 2008-02-05 2013-06-04 Allergan, Inc. Substituted cyclopentanes having prostaglandin activity
US8748177B2 (en) * 2008-09-30 2014-06-10 The Hospital For Sick Children Compositions for proliferation of cells and related methods
CA2819859A1 (en) 2010-12-06 2012-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth
EA033143B1 (ru) * 2012-03-21 2019-09-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Способ и применение селективного антагониста dp-2 по отношению к dp-1 для стимулирования роста волос
FR3000396A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et de doxycycline pour le traitement de la rosacee
FR3000395A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'oxymetazoline pour le traitement de la rosacee
FR3000399B1 (fr) * 2012-12-31 2015-03-27 Galderma Res & Dev Utilisation topique du laropiprant pour le traitement de la rosacee
FR3000398A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et de brimonidine pour le traitement de la rosacee
FR3000394A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et de metronidazole pour le traitement de la rosacee
FR3000397A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee
US9797903B2 (en) 2012-10-24 2017-10-24 Winthrop-University Hospital Non-invasive biomarker to identify subject at risk of preterm delivery
WO2014079805A1 (en) * 2012-11-23 2014-05-30 Boehringer Ingelheim International Gmbh Pyrazole compounds for treating hairloss
WO2014079806A1 (en) 2012-11-23 2014-05-30 Boehringer Ingelheim International Gmbh Pyrimidine compounds for treating hairloss
US20140148492A1 (en) * 2012-11-23 2014-05-29 Boehringer Ingelheim International Gmbh Bicyclosubstituted pyrazole compounds for treating hair loss
US10080771B2 (en) * 2015-01-28 2018-09-25 The Trustees Of The University Of Pennsylvania Compositions and methods for generation of human epithelial stem cells
WO2017019858A1 (en) * 2015-07-30 2017-02-02 The Trustees Of The University Of Pennsylvania Single nucleotide polymorphic alleles of human dp-2 gene for detection of susceptibility to hair growth inhibition by pgd2
WO2019050480A1 (en) * 2017-09-07 2019-03-14 Agency For Science, Technology And Research METHODS FOR SCREENING AGENTS FOR CONTROLLING HAIR / HAIR PUSH OR HAIR / HAIR CYCLE
EP3682250A4 (en) 2017-09-13 2021-03-03 Progenity, Inc. PRECLAMPSY BIOMARKERS AND RELATED SYSTEMS AND PROCEDURES
KR101857408B1 (ko) * 2018-02-28 2018-05-14 경북대학교 산학협력단 탈모 예방 또는 치료용 조성물
US10835538B2 (en) * 2018-03-28 2020-11-17 Nymox Corporation Method of treating benign prostatic hyperlasia with antibiotics
EP3934615A4 (en) * 2019-03-08 2023-01-25 The Regents Of The University Of California COMPOSITIONS AND METHODS FOR TREATMENT OF ACNE
CN110278919A (zh) * 2019-07-30 2019-09-27 罗洋 一种构建蠕形螨致玫瑰痤疮样皮损动物模型的方法
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS
CA3184282A1 (en) 2020-06-27 2021-12-30 Emre Koyuncu Composition of compounds that modulate cell metabolism and methods of use
WO2023060320A1 (en) * 2021-10-15 2023-04-20 Bod Science Limited Topical protein based formulation
CN117017929A (zh) * 2023-09-11 2023-11-10 山东奥克斯畜牧种业有限公司 一种用于提高采卵效果的组合物及其制备方法和应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI872553A (fi) 1986-06-09 1987-12-10 American Cyanamid Co Medium foer laekemedel foer lokalt bruk.
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
CA2402174A1 (en) 2000-03-09 2001-09-13 Ono Pharmaceutical Co., Ltd. Indole derivatives, process for preparation of the same and use thereof
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
FR2812192B1 (fr) * 2000-07-28 2003-01-31 Oreal Utilisation d'antagonistes de recepteur des prostaglandines ep-3 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
JP2004513660A (ja) 2000-11-22 2004-05-13 トリリウム　セラピューティクス　インコーポレーティッド 切断型ｃｄ２００
WO2002081649A2 (en) 2001-04-06 2002-10-17 The Trustees Of The University Of Pennsylvania ErbB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF
JPWO2003022814A1 (ja) 2001-09-07 2004-12-24 小野薬品工業株式会社 インドール誘導体化合物
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
WO2003077947A1 (en) 2002-03-15 2003-09-25 Schering Corporation Methods of modulating cd200 receptors
WO2003078409A1 (fr) 2002-03-19 2003-09-25 Ono Pharmaceutical Co., Ltd. Composes d'acide carboxylique et medicaments renfermant les composes comme principe actif
AU2003231513A1 (en) 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Pgd2 receptor antagonist
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
CA2491466A1 (en) * 2002-07-09 2004-01-15 Sharlene Adams Methods and compositions relating to isoleucine boroproline compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
JP2006508077A (ja) 2002-10-04 2006-03-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症疾患を治療するためのｐｇｄ２レセプタアンタゴニスト
AU2003269327A1 (en) 2002-10-21 2004-05-04 Warner-Lambert Company Llc Tetrahydroquinoline derivatives as crth2 antagonists
FI116400B (fi) 2002-11-19 2005-11-15 Metso Paper Inc Paperi- tai kartonkikoneen puristinosa
WO2004060295A2 (en) 2002-12-27 2004-07-22 Schering Corporation Methods of inducing and maintaining immune tolerance
EP1435356A1 (en) 2003-01-06 2004-07-07 Warner-Lambert Company LLC Quinoline derivatives as CRTH2 antagonists
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
WO2005009342A2 (en) * 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
SE0302232D0 (sv) * 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
WO2005028455A1 (ja) 2003-09-17 2005-03-31 Ono Pharmaceutical Co., Ltd. カルボン酸化合物およびそれらを有効成分として含有する医薬組成物
WO2005040114A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds having crth2 antagonist activity
WO2005040112A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
GB2407318A (en) 2003-10-23 2005-04-27 Oxagen Ltd Substituted Indol-3-yl acetic acid derivatives
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
US20050112075A1 (en) * 2003-11-25 2005-05-26 Hwang Cheng S. Reduction of hair growth
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
DK1725553T3 (da) 2004-03-11 2008-08-18 Actelion Pharmaceuticals Ltd Tetrahydropyridoindolderivater
KR20070002085A (ko) 2004-04-07 2007-01-04 밀레니엄 파머슈티컬스 인코퍼레이티드 염증 질병을 치료하기 위한 ｐｇｄ２ 수용체 길항제
JP2007533725A (ja) 2004-04-20 2007-11-22 ファイザー・インク Ｃｒｔｈ２受容体アンタゴニストを用いたニューロパシー性疼痛処置方法
WO2006034419A2 (en) 2004-09-21 2006-03-30 Athersys, Inc. Indole acetic acids exhibiting crth2 receptor antagonism and uses thereof
EP1830793A1 (en) 2004-12-29 2007-09-12 R-Tech Ueno, Ltd. Composition and method for scalp and hair treatment
GB0505048D0 (en) 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
CA2964111A1 (en) 2005-03-29 2006-10-05 The Trustees Of The University Of Pennsylvania Methods for generating new hair folicles, treating baldness, and hair removal
WO2006123677A1 (ja) 2005-05-17 2006-11-23 Taiho Pharmaceutical Co., Ltd. 好酸球性炎症疾患の重症度および再発性の予測診断方法
RU2333763C2 (ru) 2006-02-27 2008-09-20 Дмитрий Николаевич Мясников Средство для профилактики и лечения андрогенной алопеции, очагового и себорейного облысения, жирной и густой себореи волосистой части головы, перхоти и способ его получения
GB0605743D0 (en) 2006-03-22 2006-05-03 Oxagen Ltd Salts with CRTH2 antagonist activity
SI2037967T1 (sl) 2006-06-16 2017-04-26 The Trustees Of The University Of Pennsylvania Antagonisti receptorja za prostaglandin d2 za zdravljenje androgene alopecije
RU2458918C2 (ru) 2006-07-22 2012-08-20 Оксаген Лимитед Соединения, обладающие антагонистической активностью по отношению к crth2
EP2442802A1 (en) 2009-06-17 2012-04-25 Aderans Research Institute, Inc. Methods and compositions for increasing trichogenic potency of dermal cells
SG177736A1 (en) 2009-07-31 2012-02-28 Panmira Pharmaceuticals Llc Dermal formulations of dp2 receptor antagonists
US8771765B1 (en) 2009-12-22 2014-07-08 Ailin Fernandez Method and composition for treatment of hair loss
US20100172865A1 (en) 2010-03-18 2010-07-08 Shantha Totada R Methods of enhancing hair growth
CA2819859A1 (en) 2010-12-06 2012-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth
EA033143B1 (ru) 2012-03-21 2019-09-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Способ и применение селективного антагониста dp-2 по отношению к dp-1 для стимулирования роста волос

Also Published As

Publication number Publication date
EP2037967A4 (en) 2010-07-07
US20160346186A1 (en) 2016-12-01
EP3175856A1 (en) 2017-06-07
WO2007149312A3 (en) 2009-04-02
US20110021599A1 (en) 2011-01-27
DK2037967T3 (en) 2017-03-13
SI2037967T1 (sl) 2017-04-26
US10849841B2 (en) 2020-12-01
PT2037967T (pt) 2017-03-14
EP2037967A2 (en) 2009-03-25
CY1118737T1 (el) 2018-03-07
US9254293B2 (en) 2016-02-09
EP2037967B1 (en) 2016-12-07
WO2007149312A2 (en) 2007-12-27
US9889082B2 (en) 2018-02-13
US20190380942A1 (en) 2019-12-19
HUE030850T2 (en) 2017-06-28
PL2037967T3 (pl) 2017-07-31

Similar Documents

Publication Publication Date Title
ES2618352T3 (es) Antagonistas del receptor de prostaglandina D2 para el tratamiento de la alopecia androgenética
RU2404979C2 (ru) 2,4-ди(аминофенил)пиримидины в качестве ингибиторов рlk-киназ
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
PE20070181A1 (es) DERIVADOS DE CICLOHEXILAMINISOQUINOLONA COMO INHIBIDORES DE Rho-QUINASA
AR032624A1 (es) Derivados de fenilamina ciclica, uso de los mismos para la fabricacion de medicamentos y composicion farmaceutica
AR058703A1 (es) Triazolopiridazinas inhibidoras de tirosinquinasas, metodo de preparacion, composiciones farmaceuticas que las contienen y usos terapeuticos en el tratamiento del cancer
AR048315A1 (es) Compuestos heterociclicos inhibidores de la produccion de citocinas; composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades inflamatorias y oncologicas.
AR069832A1 (es) Inhibidores de la polimerasa virica
AR063331A1 (es) Derivados de biaril eter urea y composiciones farmaceuticas
AR059138A1 (es) Derivados de 1,2,4-triazol antagonistas de edg-1
RU2004132204A (ru) Имидазоконденсированные соединения
AR048641A1 (es) Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame
AR039403A1 (es) Derivados de acil-4-carboxifenilurea y su uso como antidiabetico
AR050430A1 (es) Analogos de dipeptidos inhibidores de la hepatitis c
RU2008142600A (ru) Органическое соединение
AR047537A1 (es) Piridazinonaureas como antagonistas de integrinas
AR073688A1 (es) Agonistas de receptores cb2, derivados de oxazoles y/o triazoles, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, enfermedades autoinmunes y alergicas, entre otras.
AR078786A1 (es) Derivados de la cromenona
AR054799A1 (es) Derivados de oxindol
AR039112A1 (es) Inhibidores de quinasas
AR076038A1 (es) Derivados de esteroide [3,2-c]pirazol con actividad glucocorticoide"
PE20141674A1 (es) Derivados de heterociclos biciclicos para el tratamiento de la hipertension arterial pulmonar
AR044342A1 (es) Derivados de bencimidazol
AR020551A2 (es) Compuestos macrolidos, composiciones y su uso para la preparacion de medicamentos.
AR080074A1 (es) Naftiridinas sustituidas y su uso como medicamentos